Pulmatrix Inc

Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases using its patented iSPERSE™ engineered dry powder delivery platform. The company's proprietary pipeline includes PUR3100 (inhaled dihydroergotamine for acute migraine, Phase 2-ready with FDA IND acceptance), PUR1900 (inhaled itraconazole for fungal respiratory infections, partnered with Cipla Technologies and approved for Phase 3 in India), and PUR1800 (a narrow spectrum kinase inhibitor for acute exacerbations of COPD). The iSPERSE™ technology is also licensed to MannKind Corporation and Cipla Technologies for certain fields of use. The company has no revenue and all internal clinical development is on hold. Pulmatrix is pursuing a merger with Eos SENOLYTIX, a biotechnology company developing gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, with the transaction expected to close in Q3 2026. The company's patent portfolio includes approximately 142 granted patents and 49 pending applications. Updated Aug 13, 2026